Related Experiment Video
Updated: Dec 20, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Targeting Human Lung Adenocarcinoma with a Suppressor of Mitochondrial Superoxide Production
Nivea Dias Amoedo1,2,3, Laetitia Dard1,2,3, Saharnaz Sarlak2,3
1CELLOMET, Functional Genomics Center (CGFB), Bordeaux, France.
Abstract:
REDOX signaling from reactive oxygen species (ROS) generated by the mitochondria (mitochondrial reactive oxygen species [mtROS]) has been implicated in cancer growth and survival. Here, we investigated the effect of 5-(4-methoxyphenyl)-3H-1,2-dithiole-3-thione (AOL), a recently characterized member of the new class of mtROS suppressors (S1QELs), on human lung adenocarcinoma proteome reprogramming, bioenergetics, and growth. AOL reduced steady-state cellular ROS levels in human lung cancer cells without altering the catalytic activity of complex I. AOL treatment induced dose-dependent inhibition of lung cancer cell proliferation and triggered a reduction in tumor growth in vivo. Molecular investigations demonstrated that AOL reprogrammed the proteome of human lung cancer cells. In particular, AOL suppressed the determinants of the Warburg effect and increased the expression of the complex I subunit NDUFV1 which was also identified as AOL binding site using molecular modeling computer simulations. Comparison of the molecular changes induced by AOL and MitoTEMPO, an mtROS scavenger that is not an S1QEL, identified a core component of 217 proteins commonly altered by the two treatments, as well as drug-specific targets. This study provides proof-of-concept data on the anticancer effect of AOL on mouse orthotopic human lung tumors. A unique dataset on proteomic reprogramming by AOL and MitoTEMPO is also provided. Lastly, our study revealed the repression of NDUFV1 by S1QEL AOL. Our findings demonstrate the preclinical anticancer properties of S1QEL AOL and delineate its mode of action on REDOX and cancer signaling.
Insights
The novel compound AOL, a mitochondrial reactive oxygen species (mtROS) suppressor, effectively inhibits lung cancer growth by reprogramming cellular proteomes and suppressing the Warburg effect. This study demonstrates AOL
Area of Science:
- Biochemistry
- Oncology
- Molecular Biology
Background:
- Mitochondrial reactive oxygen species (mtROS) play a crucial role in cancer cell proliferation and survival.
- Targeting mtROS offers a potential therapeutic strategy for cancer treatment.
- 5-(4-methoxyphenyl)-3H-1,2-dithiole-3-thione (AOL) is a novel mtROS suppressor belonging to the S1QEL class.
Purpose of the Study:
- To investigate the effects of AOL on proteome reprogramming, bioenergetics, and growth of human lung adenocarcinoma.
- To elucidate the molecular mechanisms underlying AOL's anticancer activity.
Main Methods:
- Cellular ROS level assessment in human lung cancer cells.
- Analysis of proteomic changes, bioenergetics, and cell proliferation.
- In vivo tumor growth studies in mouse models.
- Molecular modeling for identifying AOL binding sites.
Main Results:
- AOL reduced cellular ROS levels without affecting Complex I activity.
- AOL demonstrated dose-dependent inhibition of lung cancer cell proliferation and reduced tumor growth in vivo.
- AOL suppressed Warburg effect determinants and increased NDUFV1 expression, identified as an AOL binding site.
- Proteomic analysis revealed common and drug-specific targets when compared to MitoTEMPO, another mtROS scavenger.
Conclusions:
- AOL exhibits preclinical anticancer properties against human lung tumors.
- AOL functions by reprogramming the cancer cell proteome, impacting REDOX and cancer signaling pathways.
- The study highlights AOL's potential as a novel therapeutic agent for lung adenocarcinoma.
Related Concept Videos
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Targeted Cancer Therapies
There are several types of targeted therapies against...

